Literature DB >> 31711633

Incremental Cost of Acute Kidney Injury after Percutaneous Coronary Intervention in the United States.

Amit P Amin1, Christian McNeely2, John A Spertus3, Richard G Bach2, Nathan Frogge2, Samuel Lindner2, Sudhir Jain2, Steven M Bradley4, Jason H Wasfy5, Abhinav Goyal6, Thomas Maddox2, John A House7, Hemant Kulkarni8, Frederick A Masoudi9.   

Abstract

Contrast-induced acute kidney injury (AKI) is a common and severe complication of percutaneous coronary intervention (PCI). Despite its substantial burden, contemporary data on the incremental costs of AKI are lacking. We designed this large, nationally representative study to examine: (1) the independent, incremental costs associated with AKI after PCI and (2) to identify the departmental components of cost contributing to the incremental costs associated with AKI. In this observational cross-sectional study from the Premier database, we analyzed 1,443,297 PCI patients at 518 US hospitals from 1/2006 to 12/2015. Incremental cost of AKI from a hospital perspective obtained by a microcosting approach, was estimated using mixed-effects, multivariable linear regression with hospitals as random effects. Costs were inflation-corrected to 2016 US$. AKI occurred in 82,683 (5.73%) of the PCI patients. Those with AKI had higher hospitalization cost than those without ($38,869, SD 42,583 vs $17,167 SD 13,994, p <0.001). After adjustment, the incremental cost associated with an AKI was $9,448 (95% confidence interval $9,338 to $9,558, p <0.001). AKI was also independently associated with an incremental length of stay of 3.6 days (p <0.001). Room and board costs were the largest driver of AKI costs ($4,841). Extrapolated to the United States, our findings imply an annual AKI cost burden of 411.3 million US$. In conclusion, in this national study of PCI patients, AKI was common and independently associated with ∼$10,000 incremental costs, implying a substantial burden of AKI costs in US hospitals. Successful efforts to prevent AKI in patients who underwent PCI could result in meaningful cost savings.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2019        PMID: 31711633     DOI: 10.1016/j.amjcard.2019.09.042

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   3.133


  7 in total

1.  Effect of Clinical Decision Support With Audit and Feedback on Prevention of Acute Kidney Injury in Patients Undergoing Coronary Angiography: A Randomized Clinical Trial.

Authors:  Matthew T James; Bryan J Har; Benjamin D Tyrrell; Peter D Faris; Zhi Tan; John A Spertus; Stephen B Wilton; William A Ghali; Merril L Knudtson; Tolulope T Sajobi; Neesh I Pannu; Scott W Klarenbach; Michelle M Graham
Journal:  JAMA       Date:  2022-09-06       Impact factor: 157.335

2.  Absolute zero-contrast percutaneous coronary intervention under intravascular ultrasound guidance in chronic kidney disease patients - From despair to hope?

Authors:  Prathap Kumar; Blessvin Jino; Stalin Roy; Ali Shafeeq; Manu Rajendran
Journal:  Int J Cardiol Heart Vasc       Date:  2022-05-16

3.  Association of acute kidney injury and clinical outcomes in patients with COVID-19 in Shenzhen, China: a retrospective cohort study.

Authors:  Li-Shan Tan; Xiao-Yan Huang; Yun-Feng Wang; Yan Jia; Qi-Lin Pang; Wei-Xing Zhang; Zu-Ying Xiong; Lei Huang; Jin-Xiu Li
Journal:  Am J Transl Res       Date:  2020-10-15       Impact factor: 4.060

4.  Randomized Controlled Trial Evidence of Cost-Effectiveness of a Multifaceted AKI Intervention Approach.

Authors:  Nicholas M Selby; Luís Korrodi-Gregório; Anna Casula; Nitin V Kolhe; Daniel Ribes Arbonés; Katelyn D Bukieda; Deepak Sahu; Chris Rao; Giacomo Basadonna
Journal:  Kidney Int Rep       Date:  2020-12-16

5.  Machine learning prediction model of acute kidney injury after percutaneous coronary intervention.

Authors:  Toshiki Kuno; Takahisa Mikami; Yuki Sahashi; Yohei Numasawa; Masahiro Suzuki; Shigetaka Noma; Keiichi Fukuda; Shun Kohsaka
Journal:  Sci Rep       Date:  2022-01-14       Impact factor: 4.996

6.  Transradial Access for High-Risk Percutaneous Coronary Intervention: Implications of the Risk-Treatment Paradox.

Authors:  Amit P Amin; Sunil V Rao; Arnold H Seto; Manoj Thangam; Richard G Bach; Samir Pancholy; Ian C Gilchrist; Prashant Kaul; Binita Shah; Mauricio G Cohen; Ty J Gluckman; Anna Bortnick; James T DeVries; Hemant Kulkarni; Frederick A Masoudi
Journal:  Circ Cardiovasc Interv       Date:  2021-07-13       Impact factor: 6.546

7.  Elevated TyG Index Predicts Incidence of Contrast-Induced Nephropathy: A Retrospective Cohort Study in NSTE-ACS Patients Implanted With DESs.

Authors:  Mingkang Li; Linqing Li; Yuhan Qin; Erfei Luo; Dong Wang; Yong Qiao; Chengchun Tang; Gaoliang Yan
Journal:  Front Endocrinol (Lausanne)       Date:  2022-02-22       Impact factor: 5.555

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.